124 related articles for article (PubMed ID: 37883026)
21. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis.
Young K; Paz-Ares L; Thatcher N; Spigel DR; Shahidi J; Soldatenkova V; Grau G; Kurek R; Shepherd FA
Thromb Res; 2018 Jul; 167():50-56. PubMed ID: 29787943
[TBL] [Abstract][Full Text] [Related]
22. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
23. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism in non-small cell lung cancer patients who underwent surgery after induction therapy.
Kaminuma Y; Tanahashi M; Suzuki E; Yoshii N; Niwa H
Gen Thorac Cardiovasc Surg; 2020 Oct; 68(10):1156-1162. PubMed ID: 32274676
[TBL] [Abstract][Full Text] [Related]
25. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
Kuderer NM; Poniewierski MS; Culakova E; Lyman GH; Khorana AA; Pabinger I; Agnelli G; Liebman HA; Vicaut E; Meyer G; Shepherd FA
Oncologist; 2018 Feb; 23(2):247-255. PubMed ID: 28951500
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients.
Wang Z; Yan HH; Yang JJ; Wang BC; Chen HJ; Zhou Q; Xu CR; Jiang BY; Wu YL
Support Care Cancer; 2015 Mar; 23(3):635-41. PubMed ID: 25155313
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
[TBL] [Abstract][Full Text] [Related]
28. Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors.
Takayama Y; Nakamura T; Fukushiro Y; Mishima S; Masuda K; Shoda H
In Vivo; 2021; 35(1):467-474. PubMed ID: 33402498
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of incidence and risk factors for postoperative venous thromboembolism in patients with stageⅠ a non-small-cell lung cancer].
Dong HH; Cai YS; Liang XN; Miao JB; Chen QS; Gao YD; Li H
Zhonghua Yi Xue Za Zhi; 2021 Nov; 101(41):3417-3421. PubMed ID: 34758546
[No Abstract] [Full Text] [Related]
30. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
31. The incidence of venous thromboembolism among patients with primary lung cancer.
Chew HK; Davies AM; Wun T; Harvey D; Zhou H; White RH
J Thromb Haemost; 2008 Apr; 6(4):601-8. PubMed ID: 18208538
[TBL] [Abstract][Full Text] [Related]
32. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
[TBL] [Abstract][Full Text] [Related]
33. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
Deschênes-Simard X; Richard C; Galland L; Blais F; Desilets A; Malo J; Cvetkovic L; Belkaid W; Elkrief A; Gagné A; Hamel MA; Orain M; Joubert P; Ghiringhelli F; Routy B; Blais N
Thromb Res; 2021 Sep; 205():29-39. PubMed ID: 34246011
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors.
Kewan T; Ko T; Flores M; Sallam Y; Haddad A; Daw H
Eur J Haematol; 2021 May; 106(5):682-688. PubMed ID: 33565130
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus
Chemotherapy and Chemotherapy].
Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of D-dimer in non-small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism.
Ke L; Cui S; Chen S; Hu B; Li H
Thorac Cancer; 2020 Sep; 11(9):2483-2492. PubMed ID: 32657038
[TBL] [Abstract][Full Text] [Related]
37. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease.
Shin SH; Park HY; Im Y; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee HY; Lee SH
Int J Cancer; 2019 Nov; 145(9):2433-2439. PubMed ID: 30807641
[TBL] [Abstract][Full Text] [Related]
38. Could PD-L1 positivity be associated with venous thrombosis in patients with non-small cell lung cancer?
Söyler Y; Akın Kabalak P; Kavurgacı S; Akyürek N; Demirağ F; Yılmaz Ü
J Thromb Thrombolysis; 2023 Feb; 55(2):382-391. PubMed ID: 36564589
[TBL] [Abstract][Full Text] [Related]
39. Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Guo MZ; Balaji A; Murray JC; Reuss JE; Steinke SM; Bennett K; Naidoo J
Clin Lung Cancer; 2023 Nov; 24(7):613-620. PubMed ID: 37419702
[TBL] [Abstract][Full Text] [Related]
40. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.
Zer A; Moskovitz M; Hwang DM; Hershko-Klement A; Fridel L; Korpanty GJ; Dudnik E; Peled N; Shochat T; Leighl NB; Liu G; Feld R; Burkes R; Wollner M; Tsao MS; Shepherd FA
Clin Lung Cancer; 2017 Mar; 18(2):156-161. PubMed ID: 27913214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
